Liver Cancer Trial, Recruiting (NCT05433467)

Liver Cancer Trial, Recruiting NCT05433467 Sponsor: Northern Jiangsu People's Hospital Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05433467 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are at least 18 years old and are willing to give formal consent to take part in the study
People who have been diagnosed with liver cirrhosis (scarring of the liver) for any reason, based on clinical assessment, imaging, or tissue testing before surgery
People who have a very small liver tumour (hepatocellular carcinoma) measuring less than 1 centimetre in diameter
People whose tumour cannot be seen on a standard CT scan (without contrast dye) or on an ultrasound scan before surgery
People whose tumour can be detected using a contrast-enhanced CT scan or an MRI scan before surgery

Who may not be able to join:

People whose liver disease has been assessed as Child-Pugh grade C, which indicates severe liver function decline (confirm with trial site)
People who have high blood pressure that is not being successfully controlled
People who have serious lung problems that significantly affect how their lungs work
People who have serious heart problems that significantly affect how their heart works

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Guo-Qing Jiang, MD, Clinical Medical College, Yangzhou University

Phone: +8651487373382

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05433467

Sponsor: Northern Jiangsu People's Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: +8651487373382

More information: https://clinicaltrials.gov/study/NCT05433467

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are at least 18 years old and are willing to give formal consent to take part in the study
People who have been diagnosed with liver cirrhosis (scarring of the liver) for any reason, based on clinical assessment, imaging, or tissue testing before surgery
People who have a very small liver tumour (hepatocellular carcinoma) measuring less than 1 centimetre in diameter
People whose tumour cannot be seen on a standard CT scan (without contrast dye) or on an ultrasound scan before surgery
People whose tumour can be detected using a contrast-enhanced CT scan or an MRI scan before surgery

Who may not be able to join:

People whose liver disease has been assessed as Child-Pugh grade C, which indicates severe liver function decline (confirm with trial site)
People who have high blood pressure that is not being successfully controlled
People who have serious lung problems that significantly affect how their lungs work
People who have serious heart problems that significantly affect how their heart works

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Northern Jiangsu People's Hospital

Registry

ClinicalTrials.gov

Start date

1 May 2022

Est. completion

30 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The position of the needle

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov